Literature DB >> 16289259

Apoptotic and cell cycle regulatory markers in uterine leiomyosarcoma.

Aliza L Leiser1, Sibyl E Anderson, Daisuke Nonaka, Shaokun Chuai, Adam B Olshen, Dennis S Chi, Robert A Soslow.   

Abstract

OBJECTIVES: The primary aim of this study was to investigate the expression of apoptotic and cell cycle regulators p53, p21, p27, bax, and bcl-2 in uterine leiomyosarcoma in order to identify molecular pathways that possibly could be important in the development of leiomyosarcoma. A secondary aim was to examine if the apoptotic and cell cycle regulatory protein expression profile of uterine leiomyosarcoma is potentially useful for clinical prognostic purposes.
METHODS: A tissue microarray representing 36 uterine leiomyosarcomas and 19 uterine leiomyomas was created with 3 representative cores from each tumor. Immunohistochemical staining was performed for bcl-2, bax, p21, p27, and p53 using standard techniques. Staining was scored 0-12 for each marker, 0-3 being negative and 4-12 positive. Outcome analyses were performed only for leiomyosarcomas. First recurrence was determined from the time of initial diagnosis. Survival was determined from the time of initial diagnosis to last follow-up.
RESULTS: Associations were found between disease type (leiomyosarcoma vs. leiomyoma) and the positivity status of p21 (43% vs. 0%, P < 0.001), p53 (54% vs. 0%, P < 0.001), and bax (34% vs. 94%, P < 0.001). bcl-2-positive leiomyosarcoma was associated with a longer time to recurrence (P = 0.02) in a univariate analysis. In a multivariate analysis, tumor stage was the only independent significant prognostic factor (P = 0.002).
CONCLUSION: The significant differential expression of apoptotic and cell cycle regulatory proteins in uterine leiomyosarcoma as compared to benign smooth muscle tumors suggests that pathways involving these proteins may be important in the development of malignant disease and, therefore, could be potential targets for molecular therapies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16289259     DOI: 10.1016/j.ygyno.2005.09.055

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  13 in total

1.  An endocrine-disrupting chemical, fenvalerate, induces cell cycle progression and collagen type I expression in human uterine leiomyoma and myometrial cells.

Authors:  Xiaohua Gao; Linda Yu; Lysandra Castro; Alicia B Moore; Tonia Hermon; Carl Bortner; Maria Sifre; Darlene Dixon
Journal:  Toxicol Lett       Date:  2010-03-15       Impact factor: 4.372

Review 2.  Practical issues in uterine pathology from banal to bewildering: the remarkable spectrum of smooth muscle neoplasia.

Authors:  Esther Oliva
Journal:  Mod Pathol       Date:  2016-01       Impact factor: 7.842

3.  Pioglitazone induces cell growth arrest and activates mitochondrial apoptosis in human uterine leiomyosarcoma cells by a peroxisome proliferator-activated receptor γ-independent mechanism.

Authors:  Ulf Lützen; Yi Zhao; Katja Lucht; Maaz Zuhayra; Marlies Marx; Ingolf Cascorbi; Juraj Culman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-09-23       Impact factor: 3.000

4.  A role for BRCA1 in uterine leiomyosarcoma.

Authors:  Deyin Xing; George Scangas; Mai Nitta; Lei He; Xuan Xu; Yevgeniya J M Ioffe; Paul-Joseph Aspuria; Cyrus Y Hedvat; Matthew L Anderson; Esther Oliva; Beth Y Karlan; Gayatry Mohapatra; Sandra Orsulic
Journal:  Cancer Res       Date:  2009-10-20       Impact factor: 12.701

Review 5.  The importance of being dead: cell death mechanisms assessment in anti-sarcoma therapy.

Authors:  Santiago Rello-Varona; David Herrero-Martín; Laura Lagares-Tena; Roser López-Alemany; Núria Mulet-Margalef; Juan Huertas-Martínez; Silvia Garcia-Monclús; Xavier García Del Muro; Cristina Muñoz-Pinedo; Oscar Martínez Tirado
Journal:  Front Oncol       Date:  2015-04-07       Impact factor: 6.244

6.  Molecular subtypes of uterine leiomyosarcoma and correlation with clinical outcome.

Authors:  Joyce N Barlin; Qin C Zhou; Mario M Leitao; Maria Bisogna; Narciso Olvera; Karin K Shih; Anders Jacobsen; Nikolaus Schultz; William D Tap; Martee L Hensley; Gary K Schwartz; Jeff Boyd; Li-Xuan Qin; Douglas A Levine
Journal:  Neoplasia       Date:  2015-02       Impact factor: 5.715

7.  Molecular mechanisms of uterine leiomyosarcomas: involvement of defect in LMP2 expression.

Authors:  Takuma Hayashi; Yuto Shimamura; Taro Saegusa; Akiko Horiuchi; Yukihiro Kobayashi; Nobuyoshi Hiraoka; Yae Kanai; Hiroyuki Aburatani; Kenji Sano; Ikuo Konishi
Journal:  Gene Regul Syst Bio       Date:  2008-07-22

8.  Conditional inactivation of Brca1, p53 and Rb in mouse ovaries results in the development of leiomyosarcomas.

Authors:  Katherine V Clark-Knowles; Mary K Senterman; Olga Collins; Barbara C Vanderhyden
Journal:  PLoS One       Date:  2009-12-31       Impact factor: 3.240

9.  Prognostic impact of Jab1, p16, p21, p62, Ki67 and Skp2 in soft tissue sarcomas.

Authors:  Sveinung W Sorbye; Thomas K Kilvaer; Andrej Valkov; Tom Donnem; Eivind Smeland; Khalid Al-Shibli; Roy M Bremnes; Lill-Tove Busund
Journal:  PLoS One       Date:  2012-10-05       Impact factor: 3.240

10.  Cyclin-dependent kinase inhibitor p27Kip1 controls growth and cell cycle progression in human uterine leiomyoma.

Authors:  Sabarish Ramachandran; Kun-Young Kwon; So-Jin Shin; Sang-Hoon Kwon; Soon-Do Cha; Insoo Bae; Chi-Heum Cho
Journal:  J Korean Med Sci       Date:  2008-08       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.